Hit-to-probe-to-lead optimization strategies: A biology perspective to conquer the valley of death

Handbook of Drug Screening: Second Edition

Volumn , Issue , 2016, Pages 21-55

  Roy, Anuradha ^a   Taylor, Byron ^a   McDonald, Peter R ^a   Price, Ashleigh ^a   Chaguturu, Rathnam ^a  

^a UNIVERSITY OF KANSAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85009684020     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (30)

1. Ohlstein EH, Johnson AG, Elliott JD, et al. New strategies in drug discovery.Methods Mol Biol 2006; 316: 1-11.
2. Zycher B, DiMasi JA,Milne C. The truth about drug innovation: Thirty-five summary case histories on private sector contributions to pharmaceutical science. Med Prog Rep 2008; 6: 1-48.
3. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: New estimates of drug development costs. J Health Econ 2003; 22(2:)151-185.
4. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates?Nat Rev Drug Discov 2004; 3(8:)711-715.
5. Lipinski CA. Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Meth 2000; 44(1:)235-249.
6. Lipinski CA, Lombardo F, Dominy BW, et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001; 46(1-3:)3-26.
7. Lipkin MJ, Stevens AP, Livingstone DJ, et al. How large does a compound screening collection need to be? Comb Chem High Throughput Screen 2008; 11(6:)482-493.
8. Feng BY, Simeonov A, Jadhav A, et al. A high-throughput screen for aggregationbased inhibition in a large compound library. J Med Chem 2007; 50(10:)2385-2390.
9. Giannetti AM, Koch BD, Browner MF. Surface plasmon resonance based assay for the detection and characterization of promiscuous inhibitors. J Med Chem 2008; 51(3:)574-580.
10. Simeonov A, Jadhav A, Thomas CJ, et al. Fluorescence spectroscopic profiling of compound libraries. J Med Chem 2008; 51(8:)2363-2371.
11. Kozikowski BA, Burt TM, Tirey DA, et al. The effect of freeze/thaw cycles on the stability of compounds in DMSO. J Biomol Screen 2003; 8(2:)210-215.
12. Wunberg T, Hendrix M, Hillisch A, et al. Improving the hit-to-lead process: Datadriven assessment of drug-like and lead-like screening hits. Drug Discov Today 2006; 11(3-4:)175-180.
13. Nuttall ME, Lee D, McLaughlin B, et al. Selective inhibitors of apoptotic caspases: Implications for novel therapeutic strategies. Drug Discov Today 2001; 6(2:)85-91.
14. Los M, Burek CJ, Stroh C, et al. Anticancer drugs of tomorrow: Apoptotic pathways as targets for drug design. Drug Discov Today 2003; 8(2:)67-77.
15. Haseneen NA, Vaday GG, Zucker S, et al. Mechanical stretch induces MMP-2 release and activation in lung endothelium: Role of EMMPRIN. Am J Physiol Lung Cell Mol Physiol 2003; 284(3:)L541-L547.
16. Werner P, Kawashima E, Reid J, et al. Organization of the mouse 5-HT3 receptor gene and functional expression of two splice variants. Brain Res Mol Brain Res 1994; 26(1-2:)233-241.
17. Eggert US, Kiger AA, Richter C, et al. Parallel chemical genetic and genome-wide RNAi screens identify cytokinesis inhibitors and targets. PLoS Biol 2004; 2(12:)e379.
18. Liu H, Huang P, Xu X, et al. Anticancer effect of celecoxib via COX-2 dependent and independent mechanisms in human gastric cancers cells. Dig Dis Sci 2008.
19. Coates AR, Hu Y. Targeting non-multiplying organisms as a way to develop novel antimicrobials. Trends Pharmacol Sci 2008; 29(3:)143-150.
20. Auld DS, Thorne N, Nguyen DT, et al. A specificmechanism for nonspecific activation in reporter-gene assays. ACS Chem Biol 2008; 3(8:)463-470.
21. Bowen WP,Wylie PG. Application of laser-scanning fluorescence microplate cytometry in high content screening. Assay Drug Dev Technol 2006; 4(2:)209-221.
22. Comley J. High content screening: Emerging importance of novel reagents/probes and pathway analysis. Drug DiscovWorld 2005; 6: 31-53.
23. Cummings MD, Farnum MA, Nelen MI. Universal screening methods and applications of ThermoFluor. J Biomol Screen 2006; 11(7:)854-863.
24. Joseph-McCarthyD, Baber JC, Feyfant E, et al. Lead optimization via high-throughput molecular docking. Curr Opin Drug Discov Devel 2007; 10(3:)264-274.
25. Tsai J, Lee JT, Wang W, et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. ProcNatl Acad Sci U S A 2008; 105(8:)3041-3046.
26. Atkinson Jr AJ, Colburn WA, DeGruttola VG, et al. Biomarkers Definitions Working Group, Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69(3:)89-95.
27. Lewin DA, Weiner MP. Molecular biomarkers in drug development. Drug Discov Today 2004; 9(22:)976-983.
28. Frank R, Hargreaves R. Clinical biomarkers in drug discovery and development. Nat Rev Drug Discov 2003; 2(7:)566-580.
29. Spalding DJ, Harker AJ, Bayliss MK. Combining high-throughput pharmacokinetic screens at the hits-to-leads stage of drug discovery. Drug Discov Today 2000; 5(12 Suppl 1:)70-76.
30. Ringeissen S. Evaluation of (Q)SAR models for the prediction of mutagenicity potential. Proceeding of 6th World Congress on Alternatives & Animal Use in the Life Sciences, 2007; 14(special edition:)469-473.